of public donations go directly to programs and research


million in grants


grants awarded


research fellows supported


top medical institutions funded in the United States and Canada

Meet Miguel Sena-Esteves, PhD

Massachusetts General Hospital

In his ACGT-funded study, Dr. Sena-Esteves explored how to use a viral strategy to create a zone of resistance in the brain where normal tissue could be modified to prevent tumors from growing, and ultimately, to destroy them. His studies revealed that adeno-associated viral vectors could do the job, but not without long-term toxicity consequences for cancer patients.

Learn More

Meet Matthias Stephan, MD, PhD

Fred Hutchinson Cancer Research Center

With support from Alliance for Cancer Gene Therapy (ACGT), a multi-disciplinary team of immunologists, bioengineers and geneticists led by Dr. Stephan is advancing new pre-clinical strategies that combine principles of bioengineering with gene therapy to improve the effectiveness of therapeutic cancer vaccines.

Learn More

Meet Daniel Powell, Jr. PhD

University of Pennsylvania, Perelman School of Medicine

With funding from Alliance for Cancer Gene Therapy (ACGT), Dr. Powell is leading a phase I clinical trial, testing a new approach to T-cell therapy he hopes will achieve dramatic results. Unlike traditional chemotherapy and radiation, Dr. Powell uses an immunotherapy approach to achieve dramatic results in women with ovarian cancer.

Learn More

Our Work

Since 2001, ACGT has been the only non-profit exclusively funding cancer cell and gene therapy research. From treating the first patients to funding today’s most innovative research — ACGT has been driving forward cell and gene therapy for cancer patients. 100% of all public donations are dedicated to funding research and program. Administrative costs are funded through a separate fund.


Cell & Gene Therapy

Cancer cell and gene research breakthroughs are changing our understanding of cancer biology and rapidly advancing new therapies like CAR-T that are changing patients’ lives. We are at the beginning of incredible advances in cancer therapy and we’ll be there at the end – with patients living cancer-free.


Brain Cancer Research Collaboration

To accelerate cellular therapies for the most deadly brain cancer in adults – glioblastoma multiforme (GBM) — Alliance for Cancer Gene Therapy, Cancer Research Institute (CRI) and the Parker Institute for Cancer Immunotherapy (PICI) are collaborating to tackle the many challenges of this complex disease



Immunotherapy for Cancer - A Discussion of New Treatments for Sarcoma and Beyond